Emerging Biomarker Tests May Enhance Early Autism Identification

The Potential of Objective Autism Screening

For decades, autism identification has primarily relied on behavioral assessments, which can lead to delays in accessing supports. Emerging research is exploring objective biomarker tests that might complement existing methods. Three approaches show particular promise but require careful evaluation:

A study in Nature identified elevated microbially-derived metabolites in the urine of some autistic children, potentially offering a screening method for a specific subgroup. However, the study involved just 53 autistic children and 48 controls, requiring validation in larger, more diverse cohorts. Researchers note these metabolites may reflect comorbidities rather than causality.

A JAMA Network Open study demonstrated that eye-tracking biomarkers could be deployed in primary care settings, analyzing 338 infants. While promising for accessibility, the predictive model requires testing against other neurodevelopmental conditions to assess specificity, as similar patterns may occur in other diagnoses.

Researchers at the Chinese University of Hong Kong are piloting an AI-powered stool test that claims 95% accuracy in early trials. While granted FDA Breakthrough Device designation, the test lacks peer-reviewed validation and details about trial design—important considerations given commercial interests in diagnostic tools.

Why This Research Matters

Earlier identification of autism—when desired by families and autistic individuals—can facilitate access to supports. Current diagnostic tools often require specialized clinicians and lengthy wait times. Biomarker tests might increase accessibility if proven reliable and integrated thoughtfully into care systems, though implementation challenges like cost, training, and equitable access remain.

Critical Considerations

Autism's neurodevelopmental diversity means no single biomarker may capture its full spectrum. The urinary metabolites appear specific to one subgroup, while gut microbiome findings show correlation without confirmed causation. Ethical concerns also arise: earlier screening could lead to stigma or unnecessary interventions, particularly for children who might develop differently without labels. Autistic self-advocates emphasize that identification tools should serve autistic people's needs—not just clinical or parental priorities—and respect neurodiversity perspectives that view autism as an identity rather than a defect.